News
In this article, published in the autumn 2012 issue of Innovations in Pharmaceutical Technology, Rob Scoffin (Cresset’s CEO) explores the chemical space around existing drug molecules to provide a lower-risk, lower-cost strategy for the discovery of new chemical entities.
Click below to read full article.
Introduction When I first started using CHARMM over 20 years ago as a PhD student, I regularly came across references ...
Cambridge, UK – 4th December 2019 – Cresset Discovery Services, provider of contract research services for early phase discovery, is ...
Cambridge, UK – 20th November 2019 – Cresset, provider of software and contract research services for small molecule drug discovery, ...